Tsumura & Co.

4540

JP3535800001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-30 am EDT			5-day change	1st Jan Change
3,800 ^JPY	+1.20%		+0.16%	+43.05%

Feb. 06	Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	CI
2023	Tsumura & Co. Announces Dividend for the second quarter ended September 30, 2023, Payable on December 5, 2023 and Provides Dividend Guidance for the Full Year Ending March 31, 2024	CI

Robit, Inc. announced that it has received ¥499 million in funding from Tsumura & Co.

February 19, 2023

Robit, Inc. announced that it has raised ¥499 million in an equity round of funding on February 20, 2023. The transaction included participation from Tsumura & Co. The company issued shares through third party allocation method.

Latest news about Tsumura & Co.

Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	Feb. 06	CI
Tsumura & Co. Announces Dividend for the second quarter ended September 30, 2023, Payable on December 5, 2023 and Provides Dividend Guidance for the Full Year Ending March 31, 2024	Nov. 07	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Ending September 30, 2023 and Full Year Ending March 31, 2024	23-08-03	CI
Tsumura & Co. Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024	23-08-03	CI
Tsumura's Fiscal 2023 Profit Falls 12.5%; Shares Slip 4%	23-05-10	MT
Tsumura & Co. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-09	CI
Tsumura & Co. Provides Consolidated Financial Guidance for the First Half and Full Year Ending March 31, 2024	23-05-09	CI
Tsumura & Co. Announces Year End Dividend for the Fiscal Year Ended March 31, 2023, and Provides Second Quarter and Year End Dividend Forecast for the Fiscal Year Ending March 31, 2024	23-05-09	CI
Kontafarma China Unit to Sell 66% Equity Interest of Shaanxi Unisplendour for 168.2 Million Yuan; Shares Slip 7%	23-04-14	MT
Robit, Inc. announced that it has received ¥499 million in funding from Tsumura & Co.	23-02-19	CI
Tsumura & Co. Provides Dividend Guidance for the Full Year Ending March 31, 2023	23-02-03	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-03	CI
Tsumura & Co. Announces Dividend for the Period Ended September 30, 2022, Payable on December 5, 2022 and Provides Dividend Guidance for the Full Year Ending March 31, 2023	22-11-04	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-11-04	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-08-05	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023	22-08-05	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-05-10	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023	22-05-10	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	22-02-04	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022	22-02-04	CI
Tsumura & Co. Provides Earnings Guidance for the Year Ending March 31, 2022	21-11-05	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	21-11-05	CI
Tsumura & Co's Attributable Profit Climbs 34% in Fiscal Q1	21-08-09	MT
Tsumura & Co. Announces Consolidated Earnings Results for the First Quarter of Year Ending March 31, 2022	21-08-05	CI
Tsumura & Co. Provides Earning Provides Earnings Forecast for the First Half and Full Year of Year Ending March 31, 2022	21-08-05	CI

Chart Tsumura & Co.

Duration

Period

More charts

Company Profile

TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Tsumura & Co.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3,800 JPY

Average target price

4,920 JPY

Spread / Average Target

+29.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TSUMURA & CO.	+43.05%	1.82B
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B

Other Pharmaceuticals

Tsumura & Co.

Equities

4540

JP3535800001

Pharmaceuticals

Robit, Inc. announced that it has received ¥499 million in funding from Tsumura & Co.

EPS Revisions